Volume 18, Issue 2 (9-2004)                   Med J Islam Repub Iran 2004 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
NABIPOUR I, HAJI-GHASEMI F, KIAI S, BARADAR-JALILI R, AZIZI F. THE MUTATIONS OF RET PROTO-ONCOGENE IN MEDULLARY THYROID CARCINOMAS IN IRAN. Med J Islam Repub Iran 2004; 18 (2) :95-99
URL: http://mjiri.iums.ac.ir/article-1-624-en.html
THE MUTATIONS OF RET PROTO-ONCOGENE IN MEDULLARY THYROID CARCINOMAS IN IRAN
IRAJ NABIPOUR , FATEMEH HAJI-GHASEMI , SHAHRIAR KIAI , REZA BARADAR-JALILI , FEREIDOUN AZIZI
From the Endocrine Research Center; Shaheed Beheshti University of Medical Sciences, Tehran, the Persian Gulf Health Research Center; Bushehr University of Medical Sciences, Bushehr and the Endocrine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:   (4428 Views)
MeduIIary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between true sporadic MTC and a new mutation familial case is important for future clinical management of both the patient and family. The susceptibility gene for hereditary MTC is the RET proto-oncogene. DNA analysis for germline mutations of the RET proto-oncogene was performed in a series of 24 patients with MTC [apparently sporadic MTC (20 cases), familial MTC (2 cases), MEN 2A (one case) and MEN 2B (one case)] to determine whether they were true sporadic cases or hereditary forms. Genomic DNA was amplified using polymerase chain reaction (PCR) and oligonucleotide primers for exons 10 & I 1. The PCR products were examined by restriction enzymes analysis to detect the mutations. One of the 20 patients with apparent sporadic MTC had exon 10 mutation (Cys-620 Arg) and exon I I mutation (Cys- 634 Trp) was also found in the index case with MEN 2A. No mutation was detected in the other patients. Three of six evaluated members of the MEN 2A patient had the same mutation. We conclude that routine application of RET proto-oncogene testing should be included in all cases of apparent sporadic MTC.
Full-Text [PDF 349 kb]   (1915 Downloads)    
Type of Study: Original Research: Clinical Science | Subject: Endocrinology
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.